Imidazoline receptors I2: Looking for new therapeutic targets UNIVERSITY OF BARCELONA An article published in the Journal of Medicinal Chemistry shows a new family of molecules with high affinity to join imidazoline receptors, which are altered in the brain of those patients with neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Huntington’s. According to the preclinical...
by Perelman School of Medicine at the University of Pennsylvania Delivering the medication dantrolene through the nose rather than the mouth may help the medication penetrate the brain more effectively, potentially maximizing its therapeutic benefits in the treatment of neurodegenerative diseases, like Alzheimer’s disease. In a first-of-its-kind study, researchers in the Perelman School of Medicine...
Columbia-led team harnesses two powerful technologies to identify promising targets for diagnosing and treating neurodegenerative diseases THE ZUCKERMAN INSTITUTE AT COLUMBIA UNIVERSITY NEW YORK — The protein tau has long been implicated in Alzheimer’s and a host of other debilitating brain diseases. But scientists have struggled to understand exactly how tau converts from its normal,...
by The Chinese University of Hong Kong, Shenzhen A synthetic small molecule compound called AQAMAN can prevent and even reverse harmful protein build-up in neurons that is associated with several rare neurodegenerative disorders, including polyglutamine (or polyQ) diseases. People with polyQ diseases, such as Huntington’s and Machado-Joseph diseases, lose muscle control and coordination as nerve...
by Katherine Fenz, Rockefeller University All neurodegenerative diseases have a common thread: the appearance of protein clumps in the brain such as amyloid-beta plaques in Alzheimer’s disease and alpha synuclein aggregates in Parkinson’s. The root cause of this buildup has been hard to pinpoint, but Rockefeller scientists have identified a likely culprit that opens up...
By Osman Shabir, M.Sc. | Reviewed by Dr. Jennifer Logan, MD, MPH Parkinson’s disease is a neurodegenerative disorder clinically characterized by dyskinesia (impairment of movement), resting tremor, bradykinesia (slow movements), dystonia (stiffness of muscles including facial muscles), a stooped posture, drooling, sexual and urinary dysfunction, and in some cases psychiatric symptoms including psychosis, dementia, and depression....
This news or article is intended for readers with certain scientific or professional knowledge in the field. Researchers have found a way to create a super-inhibitor that effectively stops the development of Parkinsons by using the Parkinson disease itself as an active building block. Various neurodegenerative diseases such as Parkinson’s are closely linked to the...
Reviewed by Kate Anderton, B.Sc. (Editor) A collaborative study published today in the journal Cell Reports provides evidence for a new molecular cause for neurodegeneration in Alzheimer’s disease. The study, led by researchers at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, integrates data from human brain autopsy samples...
Human body is like a huge robot, which has its movement and electronics. We are partially mechanical and partially electronic, but the most mysterious part is how these two mediums connect together. Scientists from the University of Edinburgh and the University of Oxford found two molecules that are responsible for connecting nerves with muscles. These...
by Mary L. Martialay, Rensselaer Polytechnic Institute A new imaging technique that makes it possible to match motor proteins with the cargo they carry within a cell is upending a standard view of how cellular traffic reaches the correct destination. The research, which focuses on neurons and sheds light on some neurodegenerative diseases, was published...
